Get the Stockscreener App
46.66
1.04%
0.48
Pre-market:
46.85
0.19
+0.41%
Tempus Ai Inc stock is traded at $46.66, with a volume of 4.37M.
It is up +1.04% in the last 24 hours and down -10.48% over the past month.
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
See More
Previous Close:
$46.18
Open:
$47.08
24h Volume:
4.37M
Relative Volume:
0.79
Market Cap:
$8.38B
Revenue:
$1.36B
Net Income/Loss:
$-302.91M
P/E Ratio:
-27.16
EPS:
-1.7182
Net Cash Flow:
$-219.93M
1W Performance:
+2.48%
1M Performance:
-10.48%
6M Performance:
-39.57%
1Y Performance:
-25.42%
1-Day Range:
$46.22
$48.21
1-Week Range:
$44.30
$48.21
52-Week Range:
$41.73
$104.32
Tempus Ai Inc Stock (TEM) Company Profile
Name
Tempus Ai Inc
Sector
Industry
Phone
800-976-5448
Address
600 WEST CHICAGO AVENUE, CHICAGO
Compare TEM vs VEEV, BTSG, HQY, HNGE
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TEM
Tempus Ai Inc
|
46.66 | 8.29B | 1.36B | -302.91M | -219.93M | -1.7182 |
VEEV
Veeva Systems Inc
|
158.54 | 26.14B | 3.20B | 908.91M | 1.39B | 5.4168 |
BTSG
Brightspring Health Services Inc
|
60.32 | 11.34B | 13.65B | 169.86M | 412.12M | 1.0758 |
HQY
Healthequity Inc
|
87.25 | 7.39B | 1.31B | 215.20M | 408.32M | 2.4627 |
HNGE
Hinge Health Inc
|
52.98 | 4.28B | 646.34M | -512.40M | 202.76M | -6.6871 |
Tempus Ai Inc Stock (TEM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | Jefferies | Underperform |
| Apr-13-26 | Upgrade | TD Cowen | Hold → Buy |
| Feb-19-26 | Initiated | Mizuho | Outperform |
| Feb-17-26 | Initiated | Robert W. Baird | Outperform |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Oct-21-25 | Downgrade | TD Cowen | Buy → Hold |
| Oct-20-25 | Initiated | Canaccord Genuity | Buy |
| Sep-02-25 | Initiated | H.C. Wainwright | Buy |
| Apr-21-25 | Initiated | BTIG Research | Buy |
| Feb-25-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-12-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Feb-05-25 | Resumed | TD Cowen | Buy |
| Dec-13-24 | Initiated | Wolfe Research | Outperform |
| Dec-09-24 | Initiated | Guggenheim | Buy |
| Nov-11-24 | Downgrade | Stifel | Buy → Hold |
| Oct-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-12-24 | Initiated | Piper Sandler | Neutral |
| Jul-09-24 | Initiated | BofA Securities | Buy |
| Jul-09-24 | Initiated | JP Morgan | Overweight |
| Jul-09-24 | Initiated | Longbow | Buy |
| Jul-09-24 | Initiated | Loop Capital | Buy |
| Jul-09-24 | Initiated | Morgan Stanley | Overweight |
| Jul-09-24 | Initiated | Needham | Buy |
| Jul-09-24 | Initiated | Stifel | Buy |
| Jul-09-24 | Initiated | TD Cowen | Buy |
| Jul-09-24 | Initiated | William Blair | Outperform |
View All
Tempus Ai Inc Stock (TEM) Latest News
Tempus AI Expands Precision Oncology With New Prostate Test And ASCO Data - Yahoo! Finance Canada
Tempus AI (TEM) director Eric Belcher receives 5,913-share RSU grant - Stock Titan
Tempus AI (TEM) director awarded 5,913 RSUs vesting by 2027 meeting - Stock Titan
Tempus Announces 37 Abstracts Accepted for Presentation at the 2026 American Society of Clinical Oncology Annual Meeting - Business Wire
Wellington Shields Capital Management LLC Buys Shares of 23,594 Tempus AI, Inc. $TEM - MarketBeat
Handelsbanken Fonder AB Purchases Shares of 31,600 Tempus AI, Inc. $TEM - MarketBeat
Tempus AI, Inc. (TEM) Stock Analysis: A Balanced Look At Its 45% Potential Upside - DirectorsTalk Interviews
Tempus AI, Inc. Class A Common Stock (TEM) Live Share Price, Invest From India - INDmoney
Tempus AI (TEM) Launches ArteraAI Prostate Test, The First Externally Developed Digital Pathology Algorithm - Insider Monkey
Tempus AI Expands Cancer Platform With Launch of ArteraAI Prostate Test For Metastatic Patients - Stocktwits
Tempus AI, Inc. (TEM) and Bristol Myers Announce a Strategic Partnership - Insider Monkey
Tempus AI (NASDAQ: TEM) investors choose 3-year say-on-pay cycle - Stock Titan
Tempus AI Stock (TEM) Opinions on Fund Holdings and Trading Strategies - Quiver Quantitative
Tempus AI: Taking Advantage Of Investor Myopia (NASDAQ:TEM) - Seeking Alpha
Tempus releases digital test for prostate cancer prognosis - Crain's Chicago Business
TEM Stock Chart | TEMPUS AI INC-CL A (NASDAQ:TEM) - ChartMill
Tempus AI Insiders Sold Shares Worth Over $1.5M - TradingView
Tempus AI (TEM) Diagnostics CEO sells 1,580 shares for RSU tax withholding - Stock Titan
Tempus AI (TEM) CFO’s mandated share sale covers RSU tax obligations - Stock Titan
Tempus AI (TEM) legal chief’s non-discretionary tax sell-to-cover trade - Stock Titan
Tempus AI (TEM) CEO Lefkofsky sells 22,335 shares to cover RSU taxes - Stock Titan
Tempus AI (TEM) executive logs 13,550-share tax sell-to-cover transaction - Stock Titan
Tempus AI (TEM) CAO executes mandatory sell-to-cover for RSU taxes - Stock Titan
Tempus AI Launches AI Powered Prostate Cancer Risk Test - Moomoo
Tempus launches AI prostate cancer test on its platform - Investing.com UK
Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use - Yahoo Finance
1TEM.MI Stock Price, Quote & Chart | TEMPUS AI INC-CL A (BIT:1TEM) - ChartMill
TEM (NASDAQ: TEM) director reports sale of 2,902 shares for $171K - Stock Titan
James W. Rogers sells 21,498 shares at TEM (NASDAQ: TEM) - Stock Titan
[144] Tempus AI, Inc. SEC Filing - Stock Titan
TEM (NASDAQ: TEM) notice: insider plans to sell RSU-derived Class A shares - Stock Titan
TEM (NASDAQ: TEM) Rule 144 lists RSUs and two 10b5-1 sales by Andrew Polovin - Stock Titan
Eric Lefkofsky sells TEM (NASDAQ: TEM) Class A shares reported in Form 144 - Stock Titan
TEM (NASDAQ: TEM) affiliate seeks to sell 9,592 Class A shares for $566K - Stock Titan
Long term debt to total assets ratio of Tempus AI, Inc. Class A – HAM:F3M - TradingView
Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery - Benzinga
ETFs Investing in Tempus AI, Inc. Class A Stocks - TradingView
Price to sales ratio of Tempus AI, Inc. Class A – HAM:F3M - TradingView
Cash per share of Tempus AI, Inc. Class A – HAM:F3M - TradingView
Tempus AI, Inc. Class A Trade Ideas — HAM:F3M - TradingView
InvestingPro spotted Tempus AI’s 40% decline months in advance By Investing.com - Investing.com
Tempus AI Earnings Call Highlights Data-Driven Growth - TipRanks
TEM Technical Analysis | Trend, Signals & Chart Patterns | TEMPUS AI INC-CL A (NASDAQ:TEM) - ChartMill
4 Heavily Shorted AI Stocks to Watch Right Now - Schaeffer's Investment Research
Piper Sandler Maintains Tempus AI (TEM) Neutral Recommendation - MSN
US88023BAG8 Bond Analysis — Key Metrics - TradingView
AI in cardiology set to grow as Tempus projects $1.59B 2026 sales - Stock Titan
Assessing Tempus AI (TEM) Valuation After Recent Share Price Weakness - Yahoo Finance
Tempus AI, Bristol Myers Squibb Expand AI-Driven Clinical Trial Efforts - Yahoo Finance
ARK Invest Increases AI and Genomic Holdings While Reducing Semi - GuruFocus
Tempus AI And BMS Deepen AI Drug Development Ties As Losses Persist - Yahoo Finance
Tempus Ai Inc Stock (TEM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
3.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):